AI is shortening early drug discovery by accelerating target identification, molecule design and preclinical optimization. For clinical operations leaders, the implication is practical: more candidates may reach the clinic sooner, often from smaller companies, and clinical development must be ready to move at the new pace without cutting corners.

Most discussion of AI in drug discovery focuses on the science. That is understandable. Protein structure prediction advanced dramatically with…

A CRO study team usually includes a project manager who leads the study, a clinical trial manager who leads site management and monitoring, clinical research associates who monitor sites, and functional leads for data management, biostatistics, medical monitoring, safety, regulatory, and site startup. For a first-time sponsor, knowing what each role does, and which ones you will work with every week, makes it much easier to evaluate proposals and to ask the right staffing questions before you award…

Before the first participant is dosed, an emerging sponsor needs a working safety system: a safety database, a safety management plan, a medical reviewer available at all hours, clear reporting timelines, and agreed roles between the sponsor, the CRO, and any safety vendor. The first serious adverse event can arrive in the first week of dosing, and the regulatory clocks start the moment the sponsor or its delegate learns of it. A safety process that exists only on paper becomes visible very quickly…

"Are you ready for ICH E6(R3)?" is an easy question for a CRO to answer, and the answer is almost always "Yes." The more useful conversation starts with one more word: how? ICH adopted the final E6(R3) guideline on 6 January 2025, so most providers now have updated policies. Whether you are selecting a CRO or working with an existing partner, these six questions can move the discussion from policy to practice.

How will you support our oversight, beyond reporting your activity? Ask what information you will receive, when it will arrive, and how…

For most multisite industry trials in the United States, a central IRB is the faster and more consistent choice: one review of the protocol and informed consent, one place to submit amendments, and one set of approval timelines. Local IRB review still matters at many academic medical centers, which may require their own review or a formal reliance agreement, and institutional ancillary reviews continue either way. Your IRB strategy deserves a decision before the CRO is selected, because it shapes site activation more than most sponsors expect…

“On track” is reassuring, but what would make the update useful? Most sponsors have sat through a status call where every indicator was green and the CRO was confident, and they still left the meeting not entirely certain about the next milestone. In my experience, that unease says less about the CRO than about the shape of the update. A status report is built to…

Clinical trial insurance protects participants and the sponsor if someone is injured as a result of taking part in a study. In many countries it is a legal requirement, and ethics committees will not approve a trial without a valid certificate. In the United States there is no federal mandate, but institutions routinely require evidence of coverage and subject injury terms in their contracts. First-time sponsors often discover these requirements late, when they are already on the critical path to first patient…

Monitoring is frequently the largest single service line in a CRO proposal, and it is also the line most shaped by assumptions the sponsor never stated. If you ask five CROs to propose a monitoring approach, you will receive five different strategies at five different prices, and comparing them becomes guesswork. Deciding the outline of your monitoring strategy before the RFP, including the mix of on-site, remote, and centralized activities, lets every CRO price the same approach and lets you see real differences in efficiency and quality…

Validating an AI tool in a GxP clinical environment means demonstrating that it reliably does what it is intended to do, within a defined context, at a level of assurance proportionate to the risk of its outputs. Traditional computer system validation provides the foundation, but AI adds challenges around variability, training data and model drift.

Sponsors are often handed a vendor's validation package and told the tool is validated. That package may be sound. It may also…

The most effective way to find a mentor in clinical research is to ask for something specific. Name the skill or decision you want help with, choose someone who has already done it well, request a small and time-bound commitment, and arrive at the first conversation prepared. Most experienced professionals are glad to help when the request is clear, and far fewer people ask than you might expect…

The board has a date. That milestone may be tied to your next financing round, a commitment to investors, or a development plan with little room to slip.

The team needs a path.

Every sponsor eventually hears a milestone committed before the plan behind it exists. Say the board has announced first patient dosed by 31 March, meaning…

Before an RFP goes out, a sponsor should speak directly with five to ten experienced investigators and site research leaders about the study. Those conversations test the assumptions that drive timelines and cost, including how many eligible patients a site actually sees, what standard of care looks like, which competing trials are enrolling, and whether the visit schedule is realistic. The result is a stronger protocol and better inputs for every CRO you invite to bid…

CRO selection does not end when the contract is signed. The first 90 days after signature, when teams are assembled, plans are finalized and sites are approached, are when the gap between what was sold and what is delivered first appears. Sponsors who stay actively engaged through startup protect the value of everything they built during selection. In the ABRA PROOF™ Method, this is the fifth stage, Fortify the Start.

There is a natural exhale after signature. The selection took effort, the contract took longer than expected and everyone wants…

The most common reason AI projects in clinical operations fail is not weak technology. It is undefined workflow. When no one can describe precisely who does what, in what order, with what inputs and what approvals, there is nothing coherent for AI to execute or support.

This runs against the usual narrative. Technology marketing focuses on model accuracy and features. In practice, the work that determines success is…

A sponsor that builds its own clinical trial cost estimate before CRO proposals arrive reads those proposals with far more clarity. An independent estimate, built from your protocol assumptions and realistic benchmarks, shows you which bids are missing scope, which assumptions differ from yours, and which prices sit well outside a reasonable range. It also gives your board and investors a budget grounded in your study rather than in whichever proposal happened to arrive first…

The schedule of assessments is the single largest driver of what a clinical trial costs. Every visit, procedure, sample, and data point is multiplied across participants, sites, and months, and each one appears somewhere in a CRO proposal as monitoring time, data management effort, site payments, or laboratory fees. Sponsors who review their protocol for cost before the RFP goes out receive proposals that are easier to compare, and they avoid paying for data they will never use.

How does protocol design turn into cost? The chain is direct. Visits drive investigator grants and coordinator time. Procedures drive…

The board wants a date you can stand behind. Your team needs priorities. CROs need assumptions to build their proposals. You need those proposals to understand the budget. And the funding conversation needs a credible plan.

Each answer seems to depend on another answer you don’t yet have.

Meanwhile, the questions keep arriving. Can we commit to…

For most emerging biotechs, the CRO search should begin roughly six to nine months before the target date for the first participant, and earlier for a multinational or operationally complex study. That window allows about twelve weeks for a structured selection, several more weeks for contracting, and the three to six months a CRO typically needs to move from award to the first activated site. Start later, and the calendar begins making decisions that belong to you…

A CRO contract that holds is one that still works when the study changes, which it will. That means reconciling every assumption in the proposal into the contract, defining how changes are priced and approved, and making the commitments that won the award enforceable. In the ABRA PROOF™ Method, Optimize the Award is the fourth stage: we close every gap between the winning proposal, the budget, and your needs, so you are ready to go to contract.

Many sponsors treat contracting as a legal and commercial step that follows…

AI is accelerating pharmacovigilance by automating adverse event intake, case triage, coding and duplicate detection, and by supporting signal detection across large datasets. Because safety data directly affects participants, this is also where sponsors must be most rigorous about human review, validation and oversight.

Safety case processing has always been volume-heavy and deadline-driven. Expedited reporting timelines leave little room for…